4.1 Article

Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor

Related references

Note: Only part of the references are listed.
Article Hematology

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle et al.

BLOOD (2013)

Article Chemistry, Medicinal

A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1 L

Justin L. Anglin et al.

JOURNAL OF MEDICINAL CHEMISTRY (2013)

Article Biochemistry & Molecular Biology

Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L

Aravind Basavapathruni et al.

CHEMICAL BIOLOGY & DRUG DESIGN (2012)

Article Multidisciplinary Sciences

Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes

Debabrata Biswas et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Review Biotechnology & Applied Microbiology

Epigenetic modifications and human disease

Anna Portela et al.

NATURE BIOTECHNOLOGY (2010)

Review Hematology

11q23/MLL Acute Leukemia : Update of Clinical Aspects

Hayato Tamai et al.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2010)

Article Biochemistry & Molecular Biology

MLL targets SET domain methyltransferase activity to Hox gene promoters

TA Milne et al.

MOLECULAR CELL (2002)